 2
2 Materials and methods 
2.1 Chemicals and reagents  
The poly(dimethylsiloxane) (PDMS) kit was purchased from Dow Corning Corp. (Midland, USA). For 
the casting process, the PDMS agent and the curing agent were mixed in a weight ratio of 10:1 and cured at 
80 ℃ for 4 hours.  
The albumin fluorescence assay kit was purchased from Fluka (Buchs, Switzerland). The assay reagent 
was freshly prepared by mixing reagent A with reagent B in a volume ratio of 1:50. The albumin stock 
solution was prepared by dissolving 10 mg of human serum albumin (HSA) in 5 mL of Milli-Q water, and the 
albumin standard solutions were prepared from this stock solution using the diluted solution provided in the 
kit. For fluorescence detection, the samples or standard solutions (6 µL) were delivered, mixed and reacted 
with the assay reagent (30 µL) through the operation of the micropumps and micromixers. The creatinine 
assay kit was purchased from Fisher Diagnostics (Middletown, USA). The creatinine stock solution was 
prepared by dissolving 10 mg of creatinine in 10 mL of Milli-Q water, and the creatinine standard solutions 
were prepared from this stock solution using 0.1 N HCl solution. For absorbance measurements, the samples 
or standard solutions (3 µL) were delivered, mixed and reacted with the assay reagent (30 µL) through the 
operation of the micropumps and micromixers. 
2.2 Chip design 
Figure 1 is a schematic illustration of the chip design, the detailed dimensions for half of the chip, and a 
photograph of the assembled chip. As shown in Figure 1(a), layers 1 and 2 are designed to deliver standard 
solutions or samples while layers 3 and 4 are designed to deliver reagents and to perform mixing and reactions. 
The air chamber layers (layers 1 and 3) form cavities with the bottom layers (layers 2 and 4) for actuation via 
applied compressed air; the flexible PDMS membrane layers (layers 2 and 4) form liquid channels with the 
bottom layers (layers 3 and 5) for liquid delivery. A heating plate is located underneath the glass substrate 
(layer 5) that serves as a support layer and one side of the reagent channel in order to keep the reaction 
temperature at 37℃ .   
2.3 Chip fabrication 
The integrated microfluidic chip is composed of a four-layer PDMS structure and a glass substrate. The 
chip fabrication process which includes the computer-numerical-controlled (CNC) machining process for 
forming the molds, the PDMS replication process for forming inverse structures, and the bonding process can 
be referred to our previous work (Yang et al. 2009). 
2.4 Experimental setup 
The experimental setup is schematically shown in Figure 2 and consists of an EMV control module, an 
optical detection module comprising a fluorescence component and the absorbance component, and a 
temperature control module. The custom-built EMV control module is used to regulate the deflections of the 
PDMS membranes for liquid delivery and mixing. The custom-built temperature control module is used to 
maintain the temperature at 37℃ in the reaction well. Signals are measured on-chip via fluorescence detection 
for albumin and absorbance detection for creatinine. The detection system is constructed by modifying a 
commercial reflection microscope (Kuo et al. 2009). The switch between the optical filters for fluorescence 
and absorbance detection is achieved by the switching plate on the microscope. 
3 Results and discussion 
3.1 Characterization of the temperature control module 
 4
of 0.9926 is obtained. 
3.5 Clinical urine sample test 
In order to evaluate the performance of the proposed microfluidic system in measuring the 
concentrations of urinary albumin and creatinine for determining ACRs, 40 centrifuged urine samples are 
analyzed by the prototype microfluidic system and the conventional methods.   
For determining albumin concentrations based on fluorescence measurements, each of the 40 centrifuged 
urine samples are measured twenty times and the results are averaged. The CVs of these measurements range 
from 3.4% to 10.9%, which are slightly worse than those provided by the Beckman Coulter nephelemeter 
(2.3%-9.8%), indicating that the reproducibility of the proposed microchip is acceptable for clinical 
applications. Table 1 lists comparisons of sample and reagent consumption, analysis time, assay range, 
detection limit, reproducibility, and reagent types between the prototype microfluidic system and the 
conventional assays for albumin determination. For fair comparison, the data provided in Fluka’s instruction 
in which the AB 580 dyes were used to determine urinary albumin were also included. The sample and 
reagent consumption are greatly reduced to 6 µL and 30 µL, respectively. The analysis time is almost two-fold 
longer, however, this drawback can be eliminated when both albumin and creatinine concentrations are 
determined using a single microchip. The assay range is wider or comparable to conventional methods. 
Although the detection limit is not as low as those obtained by conventional methods, it is sufficiently below 
the 15-40 mg/L cutoff limit for MAU determination (Kessler et al. 1997a; Kessler et al. 1997b).  
Prior to creatinine measurements of clinical urine samples, the interference issue should be addressed. It 
is noted that many compounds normally existing in urine samples can interfere the creatinine measurements 
(Weber 1991). However, the interferences from urine samples for creatinine measurements have been found to 
be rarely observed since dilution factors as high as 50-100 (for example, a 50-fold dilution in our case) are 
required prior to measurements, leading to a diminishing effect on interferences (Sakai et al. 1995; Songjaroen 
et al. 2009). For determining creatinine concentrations based on light absorbance measurements in our system, 
each of the 40 centrifuged urine samples is diluted 50-fold in 0.1 N HCl followed by measuring the 
concentration twenty times and averaging the results. The CVs of these measurements range from 0.9% to 
5.7%, which are slightly worse than those provided by Roche Diagnostics (1.2%-2.2%) and Fisher 
Diagnostics (2.1%-4.4%), probably due to the variations in the microchips during the fabrication process. 
Similarly, Table 2 lists comparisons of the sample and reagent consumption, analysis time, assay range, 
detection limit, reproducibility, and reagent type between the prototype microfluidic system and the 
conventional assays for creatinine determination. For fair comparison, the data provided in Fisher‘s 
instruction in which the same reagent was used in our system were also included. The sample and reagent 
consumption, analysis time, and detection limit are superior to conventional methods. Although the assay 
range is not as wide as those obtained by conventional methods, it is wide enough for clinical applications by 
adjusting samples with proper dilution factors (Songjaroen et al. 2009). 
The comparisons in the two tables show that the proposed system consumes less samples and reagents 
and provides a faster analysis result when compared to conventional assays used in hospitals to determine 
MAU. Furthermore, it is less expensive due to lower reagent consumption and cost. While only one sample 
can be analyzed in our microchip in a single operation, multiple samples from different patients can be 
assayed in a conventional analyzer. This disadvantage, however, can be overcome by using a microchip with a 
network of multi-channels. In addition, when compared to other microchip technologies such as a microchip 
 6
References  
Bland JM, Altman DG (1999) Stat. Methods Med. Res. 8:135-160. 
Chan OTM, Herold DA (2006) Clin. Chem. 52:2141-2146. 
Chase HP, Marshall G, Garg SK, Harris S, Osberg I (1991) Clin. Chem. 37:2048-2052. 
Eshøj O, Feldt-Rasmussen B, Larsen ML, Mogensen EF (1987) Diabetic Med. 4: 531-533. 
Hofmann O, Wang X, deMello JC, Bradley DDC, deMello AJ (2005) Lab Chip 5:863-868. 
Husdan H, Rapoport A (1968) Clin. Chem. 14:222-238. 
Kamholz AEB, Weigl BH, Finlayson BA, Yager P (1999) Anal. Chem. 71:5340-5347. 
Kessler MA, Meinitzer A, Petek W, Wolfbeis OS (1997a) Clin. Chem. 43:996-1002. 
Kessler MA, Meinitzer A, Wolfbeis OS (1997b). Anal. Biochem. 248:180-182. 
Kessler MA, Wolfbeis OS (1992) Anal. Biochem. 200:254-259. 
Kuo CH, Wang JH, Lee GB (2009) Electrophoresis 30:3228-3235. 
Levey AS, Greene T, Kusek JW, Beck GL (2000) J. Am. Soc. Nephrol. 11:155A. 
Liao CS, Lee GB, Wu JJ, Chang CC, Hsieh TM, Huang FC, Luo CH (2005) Biosens. Bioelectron. 
20:1341-1348. 
Lin CH, Tsai CH, Fu LM (2005) J. Micromech. Microeng. 15:935-943. 
Lin CC, Tseng CC, Lee GB (2010a) Biomed. Microdevices 12:887-896. 
Lin CC, Hsu JL, Lee GB (2010b) Microfluid. Nanofluid. doi: 10.1007/s1040401006619.  
Lustgarten JA, Wenk RE (1972) Clin. Chem. 18:1419-1422. 
Lydakis C, Lip G (1998) QJM 91:381-391. 
Manz A, Graber N, Widmer HM (1990) Sensor. and Actuat. B: Chemical 1:244-248. 
Meagher RJ, Hatch AV, Renzi RF, Singh AK (2008) Lab Chip 8:2046-2053. 
Narayanan S, Appleton H (1980) Clin. Chem. 26: 1119-1126. 
Park KM, Lee SK, Sohn YS, Choi SY (2008) Electron. Lett. 44:185-186. 
Passing H, Bablok W (1983) J. Clin. Chem. Clin. Biochem. 21:709-720. 
Rowe DJF, Dawnay A, Watts GF (1990) Ann. Clin. Biochem. 27:297-312. 
Sakai T, Ohta H, Ohno N, Imai J (1995) Anal. Chim. Acta. 308:446-450.  
Songjaroen T, Maturos T, Sappat A, Tuantranont A, Laiwattanapaisal W (2009). Anal. Chim. Acta 647:78-83. 
Vigstrup J, Mogensen CE (1985) Acta Ophthalmol. 63:530-534. 
Waller K, Ward K, Mahan JD, Wismatt DK (1989) Clin. Chem. 35:755-765. 
Weber JA, van Zanten AP (1991) Clin. Chem. 37:695-700. 
Yang SY, Lin JL, Lee GB (2009) J. Microme. Microeng. 19:035020-0350208. 
專利: 微流體晶片及使用其之微蛋白尿檢測系統 (Microfluidic Chip and MAU Detection System 
Using the Same); 發明人:李國賓、林羣哲、曾進忠;中華民國專利; Filing date: 2010/12/14；filing 
number: 099143695 
 
 
 
 
 
 
 8
Table 3 The mean, range, SD and CV of the patients’ ACRs obtained by the proposed microfluidic system 
(N=20 for each patient). 
 
 
Fig. 1 (a) Exploded view of the chip, (b) detailed dimensions, and (c) a photograph of the assembled 
microchip 
 
 
 
 
 
 
 10
Fig. 5 (a) Measured fluorescence signals and (b) a calibration curve constructed from a series of albumin 
standard solutions measured by the prototype microfluidic system. 
 
Fig. 6 (a) Signals obtained from the light absorbance measurement and (b) a calibration curve constructed 
from a series of creatinine standard solutions measured by the prototype microfluidic system 
 
Fig. 7 Comparison of results obtained by the proposed microfluidic system and from the conventional 
method for measuring the ACRs. (a) Bland-Altman bias plot and (b) Passing-Bablok regression analysis. 
 
中   華   民   國  100  年    月    日 
 
 12
3. 請依學術成就、技術創新、社會影響等方面，評估研究成果之學術或應用價
值（簡要敘述成果所代表之意義、價值、影響或進一步發展之可能性）（以
500字為限） 
本研究發展出一整合型微流體晶片檢測系統以快速量測尿液中之白蛋白及肌酸肝濃
度，並以兩者之比率做為微白蛋白尿之臨床診斷依據。相較於目前在醫療院所所使用之傳
統檢測方法，本整合型微流體晶片系統不論在樣品及試劑消耗量、可分析之最低濃度、可
檢測之濃度範圍及分析時間等方面都優於現行方法。此外，在成本方面，由於在檢測白蛋
白時所使用的高特異性螢光染料並非免疫試劑，其價格較低，且不論是白蛋白檢測試劑或
肌酸酐檢測試劑，本系統的使用量上都甚小於現行方法，因此整體檢測成本可大幅降低。 
目前本系統所使用之光學模組係改裝自市售之反射式螢光顯微鏡，其體積較大且價格
不低，因此，若能建立一套微小化之光學模組，並使之可量產化，將可大大提高本系統及
方法之可應用性。所幸，微小化之光學模組在文獻上已被報導，例如 Hofmann, O.X.等人
以薄膜有機光激發二極體（thin-film organic light emitting diode）為基礎所組成之
微小化螢光系統（Lab on a Chip, 2005, 5, 863-868.）。有鑑於此，將本研究所發展之
方法及系統與微小化光學模組整合，必定可建構出一套價格便宜、快速、操作簡便且足以
取代目前現行微白蛋白尿檢測設備之系統。 
 
                            
一、參加會議經過 
IEEE MEMS 2011在墨西哥(坎昆)舉行，本次會議學生所發表之論文“Rapid 
separation and manipulation of micro-particles using optical images on 
flexible polymer devices”很榮幸獲選為poster presentation(僅20%的論文
評選為oral presentation)。本研究是利用光介電泳將不同大小的微粒子，此研
究特別之處就是在於基板是可撓式基板，這是史上第一次在光介電泳晶片上使用
可撓式基板，可撓式基板之優點為可彎曲、好攜帶、並且費用便宜，並且我們可
以藉著可撓式基板之特點，來加速分離不同大小之微粒子，在製程上我們也有改
善配溶液時之溫度，使我們的晶片成產生更大之力量，進而更易分選、分離、分
類、聚集微粒子。 
於海報論文發表時，學生與多位國際學者討論及交流各相關專業領域之心得，
並獲得許多寶貴意見，並且在海報時間時，學生都會站在海報前，並不會限定在
只有屬於自己時間才去站在海報前，此行為可以增加許多與多位國際學者討論並
交流之機會，而會議期間除了海報論文發表外，亦至各口頭發表會場聽取與自己
研究領域相關或有興趣的主題報告，以瞭解目前國際各研究單位之研究主流及方
向。 
二、與會心得 
第24屆IEEE微機電系統國際研討會(簡稱：IEEE MEMS 2011)，是微機電學門
領域中最為重要之國際研討會(論文被接受率僅約30%)，其領域包含整合微機電
系統之醫學、化學及生物等相關研究，是一個提供與會者展示最新成果、交換研
發心得與進行跨國合作的平台。 
除了選出最新科技研究成果於論文集外，本會議亦邀請多位奈米科技及微機
電系統相關領域中舉世聞名的一流學者到場進行演講，互相分享各自不同的心得
及學問，使學生所獲甚多。 
本屆會議徵文方向涵蓋下列主題:  
1. Fabrication Technologies 
2. Packaging Technologies 
3. Materials and Device Characterization 
4. Mechanical Sensors and Systems 
5. Physical MEMS (Optical, Magneto) 
六、其他 
                             
         圖一                圖二               圖三 
圖一：於海報前之照片 
圖二：於海報時間與國際學者討論交流之照片 
圖三：於會場看板前之照片 
 
 
 
國科會補助計畫
計畫名稱: 快速可拋式微流體晶片於微白蛋白尿之檢測
計畫主持人: 林羣哲
計畫編號: 99-2218-E-006-236- 學門領域: 生醫材料 
註：本項研發成果若尚未申請專利，請勿揭露可申請專利之主要內容。
其他成果 
(無法以量化表達之成
果如辦理學術活動、獲
得獎項、重要國際合
作、研究成果國際影響
力及其他協助產業技
術發展之具體效益事
項等，請以文字敘述填
列。) 
無 
 成果項目 量化 名稱或內容性質簡述 
測驗工具(含質性與量性) 0  
課程/模組 0  
電腦及網路系統或工具 0  
教材 0  
舉辦之活動/競賽 0  
研討會/工作坊 0  
電子報、網站 0  
科 
教 
處 
計 
畫 
加 
填 
項 
目 計畫成果推廣之參與（閱聽）人數 0  
國科會補助專題研究計畫成果報告自評表 
請就研究內容與原計畫相符程度、達成預期目標情況、研究成果之學術或應用價
值（簡要敘述成果所代表之意義、價值、影響或進一步發展之可能性）、是否適
合在學術期刊發表或申請專利、主要發現或其他有關價值等，作一綜合評估。
1. 請就研究內容與原計畫相符程度、達成預期目標情況作一綜合評估 
■達成目標 
□未達成目標（請說明，以 100 字為限） 
□實驗失敗 
□因故實驗中斷 
□其他原因 
說明： 
2. 研究成果在學術期刊發表或申請專利等情形： 
論文：■已發表 □未發表之文稿 □撰寫中 □無 
專利：□已獲得 ■申請中 □無 
技轉：□已技轉 □洽談中 ■無 
其他：（以 100 字為限） 
本計劃在執行期間,所發表之論文及專利情形如下: 
a.期刊論文:3 篇:(均為第一作者,其中一篇送審中) 
b.國際研討會論文:3 篇:(共同作者) 
c.專利: 微流體晶片及使用其之微蛋白尿檢測系統； 發明人:李國賓、林羣哲、曾進忠；
中華民國專利；申請案號: 099143695 
3. 請依學術成就、技術創新、社會影響等方面，評估研究成果之學術或應用價
值（簡要敘述成果所代表之意義、價值、影響或進一步發展之可能性）（以
500 字為限） 
本研究發展出一整合型微流體晶片檢測系統以快速量測尿液中之白蛋白及肌酸肝濃度，並
以兩者之比率做為微白蛋白尿之臨床診斷依據。相較於目前在醫療院所所使用之傳統檢測
方法，本整合型微流體晶片系統不論在樣品及試劑消耗量、可分析之最低濃度、可檢測之
濃度範圍及分析時間等方面都優於現行方法。此外，在成本方面，由於在檢測白蛋白時所
使用的高特異性螢光染料並非免疫試劑，其價格較低，且不論是白蛋白檢測試劑或肌酸酐
檢測試劑，本系統的使用量上都甚小於現行方法，因此整體檢測成本可大幅降低。 
目前本系統所使用之光學模組係改裝自市售之反射式螢光顯微鏡，其體積較大且價格不
低，因此，若能建立一套微小化之光學模組，並使之可量產化，將可大大提高本系統及方
法之可應用性。所幸，微小化之光學模組在文獻上已被報導，例如 Hofmann, O.X.等人以
薄膜有機光激發二極體（thin-film organic light emitting diode）為基礎所組成之微
小化螢光系統（Lab on a Chip, 2005, 5, 863-868.）。有鑑於此，將本研究所發展之方
法及系統與微小化光學模組整合，必定可建構出一套價格便宜、快速、操作簡便且足以取
代目前現行微白蛋白尿檢測設備之系統。 
 
